Astal Laboratories Ltd (ASTALLTD) — shareholding pattern, promoter holding, financials and share price
About Astal Laboratories Ltd (ASTALLTD)
Astal Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ASTALLTD and on the BSE under scrip code 512600. Its ISIN is INE307N01014.
Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs). [1]
Macro International Limited specializes in retail through a departmental store in Kanpur, offering diverse products like garments, electronics, and more.
The company successfully operates its Saree Division and Archies Card Division, maintaining relevance in select segments despite past ventures.
Listed peers in Pharmaceuticals: Albert David Ltd, Aptus Pharma Ltd, Valiant Laboratories Ltd, Medicamen Biotech Ltd, Medico Remedies Ltd, Infinium Pharmachem Ltd.
Valuation & Returns
10 Jul 2026At ₹83.96 a share on 10 Jul 2026, Astal Laboratories Ltd (ASTALLTD) was valued at a price-to-earnings ratio of 45.29x against an industry P/E of 36.41x and a price-to-book of 10.22x on a book value of ₹8.22 per share as of Mar 2025. Solomo computes return on equity of 22.56% and return on capital employed of 24.91% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 45.29x
- Industry P/E
- 36.41x
- P/B
- 10.22x
- EPS (TTM)
- ₹1.85
- Book value / share
- ₹8.22
- ROE
- 22.56%
- ROCE
- 24.91%
- ROA
- 12.82%
- Debt / equity
- 0.37x
- Dividend yield
- 0%
- 52-week range
- ₹60.45 – ₹103.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Astal Laboratories Ltd (ASTALLTD) reported revenue of ₹249 crore, net profit of ₹15 crore and earnings per share of ₹3.48. That compares with revenue of ₹64 crore and net profit of ₹9 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹134.05 crore and net profit ₹7.68 crore (consolidated).
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue (₹ cr) | 64 | 249 |
| Net profit (₹ cr) | 9 | 15 |
| EPS (₹) | 9.08 | 3.48 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | - | - | 171.59% |
| Profit growth | 117.60% | - | - | - |
| Stock price CAGR | - | 53% | 46% | -12% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 4.53% of Astal Laboratories Ltd (ASTALLTD) (down 0.17 pp QoQ). Market capitalisation was ₹368 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Sesha Sai Nikhil Chintalapati 11.38%, Suryanarayana Raju Rudraraju . 6.75%, Kommera Harish 6.43%, Amit Mishra 4.57%, Abraham George 4.4%, Liju Mathew 3.81%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 4.53% | - | - | - | 95.47% |
| Mar 2026 | 4.7% | - | - | - | 95.3% |
| Dec 2025 | 18.19% | - | - | - | 81.81% |
| Sep 2025 | 18.19% | - | - | - | 81.81% |
| Jun 2025 | 18.19% | - | - | - | 81.81% |
| Mar 2025 | 19.93% | - | - | - | 80.07% |
| Dec 2024 | 19.93% | - | - | - | 80.07% |
| Sep 2024 | 19.93% | - | - | - | 80.07% |